📉 The Global Biopharma Index shows a decline in scores, signaling issues in talent and regulation.
👩🔬 Sourcing skilled workers remains tough. Governments need to improve policies for better industry collaboration.
♻️ Sustainability goals are at risk due to short-term priorities.
🤝 The industry must adapt through cooperation to thrive.
Introduction:
The article discusses the findings from Cytiva’s third Global Biopharma Index, highlighting the challenges the biopharma industry is currently facing, including a talent shortage and regulatory issues. The report reveals a decline in the overall biopharma ecosystem’s rating and emphasizes the need for collaborative efforts to address these challenges.
- The global average score of the biopharma ecosystem in 2025 decreased to 5.96 from 6.08 in 2023, indicating growing challenges.
- Switzerland, the U.K., and South Korea are the top three countries in the index, with South Korea making significant progress due to investments in R&D and digital innovation.
- The talent pool has slightly improved, yet one-third of executives report critical shortages in skills vital for advanced drug modalities.
- Respondents noted that regulatory uncertainty and inconsistent government policies are hindering capital acquisition and overall progress.
- Collaboration among various stakeholders, including government and industry partners, is deemed essential for meeting global demands and advancing sustainability efforts.
Conclusion:
The findings from the Global Biopharma Index underscore the pressing need for the biopharma industry to enhance resilience through strategic collaborations and investments, particularly in talent development and regulatory reform. The decline in ecosystem ratings paired with significant talent shortages suggests that immediate action is required to ensure the industry’s ability to innovate and respond to future healthcare challenges.
